<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2501233167
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZERBAXA Powder For Injection Vial
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        Tazobactam,CEFTOLOZANE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.5,1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3282.10
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="STERI-PHARMA, LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            STERI-PHARMA, LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 583]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ALNAGHI COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MERCK SHARP & DOHME
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DI 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Zerbaxa is a medicine used to treat a range of bacterial infections. It contains two active substances:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ceftolozane, an antibiotic that belongs to the group of &ldquo;cephalosporins&rdquo; and which can kill certain bacteria that can cause infection;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tazobactam, which blocks the action of certain enzymes called beta-lactamases. These enzymes make bacteria resistant to ceftolozane by breaking down the antibiotic before it can act. By blocking their action, tazobactam makes ceftolozane more effective at killing bacteria.</p><p>&nbsp;</p><p>Zerbaxa is used in all age groups to treat complicated infections within the abdomen, and kidney and urinary system.</p><p>&nbsp;</p><p>Zerbaxa is also used in adults to treat an infection of the lungs called &ldquo;pneumonia&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><!--[if !supportLists]--></p><p><strong>Do not take Zerbaxa</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to ceftolozane, tazobactam or any of the other ingredients of this medicine (listed in section&nbsp;6).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to medicines known as &ldquo;cephalosporins&rdquo;.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a severe allergic reaction (e.g., severe skin peeling; swelling of the face, hands, feet, lips, tongue or throat; or difficulty swallowing or breathing) to certain other antibiotics (e.g., penicillins or carbapenems).</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking Zerbaxa if you know you are, or have previously been allergic to cephalosporins, penicillins or other antibiotics.</p><p>&nbsp;</p><p>Talk to your doctor or pharmacist if you develop diarrhoea while taking Zerbaxa.</p><p>&nbsp;</p><p>Infections caused by bacteria that are not sensitive to Zerbaxa or caused by a fungus can occur during or following treatment with Zerbaxa. Tell your doctor if you think you may have another infection.</p><p>&nbsp;</p><p>Treatment with Zerbaxa sometimes causes production of antibodies that react with your red blood cells. If you are told that you have an abnormal blood test (called Coombs test) tell your doctor that you are having or have recently had Zerbaxa.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>This medicine should not be given to children under 18&nbsp;years old to treat pneumonia because there is not enough information on use in this age group for the treatment of this infection.</p><p><strong>&nbsp;</strong></p><p><strong>Other medicines and Zerbaxa</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.</p><p>&nbsp;</p><p>Some medicines may interact with ceftolozane and tazobactam. These include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Probenecid (a medicine for gout). This can increase the time it takes for tazobactam to leave your body.</p><p>&nbsp;</p><p><strong>Pregnancy and breast‑feeding</strong></p><p>If you are pregnant or breast‑feeding, or think you may be pregnant, ask your doctor or pharmacist for advice before taking this medicine. Your doctor will advise if you should receive Zerbaxa during pregnancy.</p><p>&nbsp;</p><p>If you are breast‑feeding, your doctor will advise you on whether you should stop breast‑feeding or stop or avoid Zerbaxa therapy, taking into account the benefit of breast‑feeding for the child and the benefit of therapy for you.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Zerbaxa may cause dizziness, which can affect your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>Zerbaxa contains sodium</strong></p><p>This medicine contains 230&nbsp;mg sodium (main component of cooking/table salt) in each vial. This is equivalent to 11.5% of the recommended maximum daily dietary intake of sodium for an adult. The reconstituted vial with 10&nbsp;mL of 0.9% sodium chloride (normal saline) for injection contains 265&nbsp;mg sodium in each vial. This is equivalent to 13.3% of the recommended maximum daily dietary intake of sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Your doctor or other healthcare professional will give you this medicine into one of your veins through an infusion (a drip) lasting one hour. The dose of medicine given to you depends on whether or not you have kidney problems.</p><p>&nbsp;</p><p>The dose depends on the type of infection that you have, where the infection is in your body and how serious the infection is. Your doctor will decide on the dose that you need.</p><p>&nbsp;</p><p><strong>Use in adults</strong></p><p>The recommended dose of Zerbaxa is 1&nbsp;g of ceftolozane and 0.5&nbsp;g of tazobactam or 2&nbsp;g of ceftolozane and 1&nbsp;g of tazobactam every 8&nbsp;hours, which is given into one of your veins (directly into the bloodstream).</p><p>&nbsp;</p><p>Treatment with Zerbaxa normally lasts between 4 and 14&nbsp;days, depending on the severity and location of the infection and on how your body responds to the treatment.</p><p>&nbsp;</p><p><strong>Use in children and adolescents</strong></p><p>The recommended dose of Zerbaxa is 20&nbsp;mg/kg of ceftolozane and 10&nbsp;mg/kg of tazobactam every 8&nbsp;hours, which is given into one of your veins (directly into the bloodstream). The dose should not exceed 1&nbsp;g of ceftolozane and 0.5&nbsp;g of tazobactam.</p><p>&nbsp;</p><p>Treatment with Zerbaxa normally lasts between 5 and 14&nbsp;days, depending on the severity and location of the infection and on how your body responds to the treatment.</p><p>&nbsp;</p><p><strong>Patients with kidney problems</strong></p><p>Your doctor may need to reduce the dose of Zerbaxa or decide how often Zerbaxa is given to you. Your doctor may also want to test your blood to make sure you receive an appropriate dose, especially if you have to take this medicine for a long time.</p><p>&nbsp;</p><p><strong>If you take more Zerbaxa than you should</strong></p><p>As this product is given by a doctor or other healthcare professional, it is very unlikely that you will be given too much Zerbaxa. However, if you have any concerns you should let your doctor, nurse or pharmacist know immediately.</p><p>&nbsp;</p><p><strong>If you stop taking Zerbaxa</strong></p><p>If you think you have not been given a dose of Zerbaxa, tell your doctor or other healthcare professional immediately.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Tell your doctor straight away if you get these symptoms as you may need urgent medical treatment:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden swelling of your lips, face, throat or tongue; a severe rash; and, swallowing or breathing problems. These may be signs of a severe allergic reaction (anaphylaxis) and may be life-threatening</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea that becomes severe or does not go away or stool that contains blood or mucus during or after treatment with Zerbaxa. In this situation, you should not take medicines that stop or slow bowel movement</p><p>&nbsp;</p><p><u>Adults treated for complicated infections within the abdomen, and kidney and urinary system</u></p><p><strong>Common</strong> side effects (may affect up to 1 in 10&nbsp;people):</p><p>Headache, stomach ache, constipation, diarrhoea, nausea, vomiting, increase in liver enzymes (from blood tests), rash, fever (high temperature), decrease in blood pressure, decrease in potassium (from blood tests), increase in the number of certain types of blood cells known as platelets, dizziness, anxiety, difficulty sleeping, infusion site reactions</p><p>&nbsp;</p><p><strong>Uncommon</strong> side effects (may affect up to 1 in 100&nbsp;people):</p><p>Inflammation of the large intestine due to <em>C. difficile</em> bacteria, inflammation of the stomach, abdominal distension, indigestion, excessive gas in stomach or bowel, obstruction of the intestine, yeast infection in the mouth (thrush), yeast infection of female genitalia, fungal urinary tract infection, increase in sugar (glucose) levels (from blood tests), decrease in magnesium levels (from blood tests), decrease in phosphate levels (from blood tests), ischemic stroke (stroke caused by reduced blood flow in brain), irritation or inflammation of a vein at injection site, venous thrombosis (blood clot in a vein), low red blood cell counts, atrial fibrillation (rapid or irregular heartbeat), fast heartbeat, angina pectoris (chest pain or feeling of tightness, pressure or heaviness in chest), itchy rash or swellings on the skin, hives, Coombs test positive (a blood test that looks for antibodies that may fight against your red blood cells), kidney problems, kidney disease, shortness of breath</p><p>&nbsp;</p><p><u>Additional side effects observed in children and adolescents treated for complicated infections within the abdomen, and kidney and urinary system</u></p><p><strong>Common</strong> side effects (may affect up to 1 in 10&nbsp;people):</p><p>Increased appetite, low white blood cell counts, altered taste</p><p><strong>&nbsp;</strong></p><p><u>Adults treated for an infection of the lungs called &ldquo;pneumonia&rdquo;</u></p><p><strong>Common</strong> side effects (may affect up to 1 in 10&nbsp;people):</p><p>Inflammation of the large intestine due to <em>C.</em>&nbsp;<em>difficile</em> bacteria, diarrhoea, vomiting, increase in liver enzymes (from blood tests)</p><p><strong>&nbsp;</strong></p><p><strong>Uncommon</strong> side effects (may affect up to 1 in 100&nbsp;people):</p><p>Infection due to <em>C.</em>&nbsp;<em>difficile</em> bacteria, <em>C.</em>&nbsp;<em>difficile</em> test positive (from stool test), Coombs test positive (a blood test that looks for antibodies that may fight against your red blood cells)</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via &ldquo;The National Pharmacovigilance and Drug Safety Centre (NPC), SFDA&rdquo;. By reporting side effects you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and vial after &ldquo;EXP.&rdquo;</p><p>&nbsp;</p><p>Unopened vials: Store in a refrigerator (2&nbsp;&ordm;C&nbsp;&ndash;&nbsp;8&nbsp;&ordm;C).</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zerbaxa contains</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are ceftolozane and tazobactam.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Each vial contains ceftolozane sulfate equivalent to 1&nbsp;g ceftolozane and tazobactam sodium equivalent to 0.5&nbsp;g tazobactam. For doses above 1&nbsp;g ceftolozane and 0.5&nbsp;g tazobactam, two vials are used.</p><p>The other excipients are sodium chloride, arginine, and citric acid, anhydrous.</p><p><!--[if !supportLists]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What Zerbaxa looks like and contents of the pack
	Zerbaxa is a white to slightly yellow powder for concentrate for solution for infusion (powder for concentrate) supplied in a vial.
	
Zerbaxa is available in packs containing 20 mL Type I clear glass vial with stopper (bromobutyl rubber) and flip off seal.
	
	Pack size of 10 vials.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Merck Sharp &amp; Dohme B.V.</p><p>Waarderweg 39</p><p>2031 BN Haarlem</p><p>The Netherlands</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Steri-Pharma, LLC</p><p>429 S. West Street, NY, Syracuse, 13202, United States</p><p>&nbsp;</p><p>Fareva Mirabel - FR Route de Marsat RIOM, Clermont Ferrand Cedex 9, 63963 FR</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in {July 2022}.
	
To report any side effect(s):
•	Saudi Arabia: 
The National Pharmacovigilance Centre (NPC):
Fax: +966-11-205-7662
SFDA Call Center: 19999
E-mail: npc.drug@sfda.gov.sa
Website: https://ade.sfda.gov.sa
•	Other GCC States: 
Please contact the relevant competent authority.

This is a Medicament
•	Medicament  is  a  product  which  affects  your  health  and  its  consumption  contrary  to Instructions are dangerous for you.
•	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
•	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
•	Do not by yourself interrupt the period of treatment prescribed for you.
•	Do not repeat the same prescription without consulting your doctor.
•	Keep all medicaments out of reach of children.

Council of Arab Health Ministers  
 Union of Arab Pharmacists

This patient information leaflet is approved by the Saudi Food & Drug Authority. 
	---------------------------------------------------------------------------------------------------------------------------
	
	The following information is intended for healthcare professionals only:
	
Preparation of solutions
	
Each vial is for single use only.

Aseptic technique must be followed in preparing the infusion solution. 

Preparation of doses

The powder for concentrate for solution for infusion for each vial is reconstituted with 10 mL of water for injections or sodium chloride 9 mg/mL (0.9%) solution for injection per vial; following reconstitution the vial should be shaken gently to dissolve the powder. The final volume is approximately 11.4 mL per vial. The resultant concentration is approximately 132 mg/mL (88 mg/mL of ceftolozane and 44 mg/mL of tazobactam) per vial. 

CAUTION: THE RECONSTITUTED SOLUTION IS NOT FOR DIRECT INJECTION.

Zerbaxa solution for infusion is clear and colourless to slightly yellow.

Variations in colour within this range do not affect the potency of the product.

After reconstitution and dilution, chemical and physical in use stability has been demonstrated for 24 hours at room temperature or 4 days at 2 to 8 ºC. The medicinal product is photosensitive and should be protected from light when not stored in the original carton.

See section 4.2 of the Summary of Product Characteristics for recommended dose regimens for Zerbaxa based on indication and renal function. The preparation for each dose is shown below.

Instructions for preparing adult doses in INFUSION BAG:

For preparation of the 2 g ceftolozane / 1 g tazobactam dose: Withdraw the entire contents from two reconstituted vials (approximately 11.4 mL per vial) using a syringe and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.

For preparation of the 1.5 g ceftolozane / 0.75 g tazobactam dose: Withdraw the entire contents from one reconstituted vial (approximately 11.4 mL per vial) and 5.7 mL from a second reconstituted vial using a syringe and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.

For preparation of the 1 g ceftolozane / 0.5 g tazobactam dose: Withdraw the entire contents (approximately 11.4 mL) of the reconstituted vial using a syringe and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 

For preparation of the 500 mg ceftolozane / 250 mg tazobactam dose: Withdraw 5.7 mL of the contents of the reconstituted vial and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 

For preparation of the 300 mg ceftolozane / 150 mg tazobactam dose: Withdraw 3.5 mL of the contents of the reconstituted vial and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.

For preparation of the 250 mg ceftolozane / 125 mg tazobactam dose: Withdraw 2.9 mL of the contents of the reconstituted vial and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 

For preparation of the 100 mg ceftolozane / 50 mg tazobactam dose: Withdraw 1.2 mL of the contents of the reconstituted vial and add it to an infusion bag containing 100 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection. 

Instructions for preparing paediatric doses in INFUSION BAG or in INFUSION SYRINGE:

NOTE: The following procedure describes the steps to prepare 100 mL of stock solution with a final concentration of 10 mg/mL ceftolozane / 5 mg/mL tazobactam. The volume of this stock solution to be administered to the paediatric patient will be based on calculating the appropriate dose based on the patient’s weight (see section 4.2 of the Summary of Product Characteristics). Detailed steps and calculations are provided. 

1.	 Preparing the stock solution (100 mL of 10 mg/mL ceftolozane / 5 mg/mL tazobactam): Withdraw the entire contents (approximately 11.4 mL) of the reconstituted vial using a syringe and add it to an infusion bag containing 89 mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.
2.	Preparing the required volume of stock solution for infusion: 
a.	Calculate the appropriate amount of Zerbaxa (in mg) to deliver the required dose to the paediatric patient. Based on this dose in mg, calculate the appropriate volume of the 10 mg/mL ceftolozane / 5 mg/mL tazobactam stock solution to be administered. Refer to Table 1 below to confirm the calculations. Note that the table is NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.
b.	Transfer an appropriately calculated volume of stock solution to an adequately sized infusion bag or infusion syringe. Values shown in Table 1 are approximate, and it may be necessary to round to the nearest graduation mark of an appropriately sized syringe for smaller volumes.

Table 1: Preparation of Zerbaxa for paediatric patients (from birth* to below 18 years of age) from the 100 mL stock solution of 10 mg/mL ceftolozane / 5 mg/mL tazobactam
Zerbaxa dose (mg/kg)	Weight (kg)	Calculated amount of ceftolozane (mg)	Calculated amount of tazobactam (mg)	Volume of stock solution to administer to patient (mL)
20 mg/kg ceftolozane / 10 mg/kg tazobactam**	50 and greater	1 000	500	100
	40	800	400	80
	30	600	300	60
	20	400	200	40
	15	300	150	30
	10	200	100	20
	5	100	50	10
	3	60	30	6
	1.5	30	15	3
*Defined as > 32 weeks gestational age and ≥ 7 days postnatal.
**Children weighing > 50 kg and with eGFR > 50 mL/min/1.73 m2 should not exceed the maximum dose of 1 g ceftolozane / 0.5 g tazobactam.

From a microbiological point of view, the medicinal product should be used immediately upon reconstitution. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 ºC, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.

One of the active ingredients, ceftolozane, may have harmful effects if it reaches the aquatic environment. Do not throw away any unused medicinal product or waste material via wastewater. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. These measures will help protect the environment.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">زِرباكسا هو دواء يستخدم لعلاج مجموعة من الالتهابات البكتيرية. زِرباكسا يحتوي على اثنين من المواد الفعالة:<br />- سيفتولوزان، وهو مضاد حيوي ينتمي إلى مجموعة &quot;السيفالوسبورين&quot; والتي يمكن أن تقتل بعض البكتيريا التي قد تُسبب العدوى.<br />- تازوباكتام، الذي يمنع عمل بعض الإنزيمات تسمى بيتا لاكتاماسيس. هذه الإنزيمات تجعل البكتيريا مقاومة للسيفتولوزان عن طريق تحطيم المضادات الحيوية قبل أن يبدأ تأثيرها. وبذلك يتمكن تازوباكتام عن طريق منع عمل تلك الإنزيمات من جعل سيفتولوزان أكثر فعالية في قتل البكتيريا.</p><p>يستخدم زِرباكسا في جميع الفئات العمرية لعلاج الالتهابات المعقدة داخل البطن والكلى والجهاز البولي.</p><p dir="RTL">يستخدم زِرباكسا أيضا في البالغين لعلاج والتهابات في الرئتين تسمى &quot;الالتهاب الرئوي&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول زِرباكسا إذا</strong><br />- كان لديك حساسية نحو سيفتولوزان، تازوباكتام أو أي من المكونات الأخرى في هذا الدواء (المدرجة في الفقرة رقم 6).<br />- كان لديك حساسية نحو الأدوية المعروفة باسم &quot;السيفالوسبورين&quot;.<br />- تعرضت في السابق لرد فعل تحسسي شديد (على سبيل المثال، تقشير الجلد الشديد؛ تورم في الوجه أو اليدين أو القدمين أو الشفتين أو اللسان أو الحلق أو صعوبة في البلع أو التنفس) نحو بعض المضادات الحيوية الأخرى (مثل البنسلين أو الكاربابينيمات).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>المحاذير والإحتياطات</strong><br />تحدث مع طبيبك أو الصيدلي قبل أن تتناول زِرباكسا إذا كنت تعلم أن لديك، أو سبق وتعرضت لحساسية نحو السيفالوسبورين والبنسلين أو المضادات الحيوية الأخرى.</p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي إذا تعرّضت للإسهال أثناء تناولك زِرباكسا.</p><p dir="RTL">قد تحدث عدوى جرثومية ناجمة عن بكتيريا غير حساسة لزِرباكسا أو عن الفطريات أثناء أو بعد العلاج بزِرباكسا. أخبر طبيبك إذا كنت تعتقد أنك قد أُصبت بعدوى أخرى.</p><p dir="RTL">العلاج بزِرباكسا يسبب أحيانًا إنتاج الأجسام المضادة التي تتفاعل مع خلايا الدم الحمراء لديك. إذا أُخبرت أن لديك فحص غير طبيعي للدم (يسمى فحص كومبس &quot; اختبار ضد الغلوبولين&quot;) أخبر طبيبك أنك تتناول أو تناولت زِرباكسا مؤخرًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقين</strong><br />لا ينبغي إعطاء هذا الدواء للأطفال دون سن 18 عاما لعلاج الالتهاب الرئوي لأنه لا توجد معلومات كافية عن الاستخدام في هذه الفئة العمرية لعلاج هذه العدوى.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أدوية أخرى وزِرباكسا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخرًا، أو قد تتناول أيّ أدوية أخرى.</p><p dir="RTL">قد تتفاعل بعض الأدوية مع سيفتولوزان و تازوباكتام. وتشمل هذه:</p><p dir="RTL">- بروبينيسيد (دواء للنقرس). يمكن أن يزيد هذا الدواء من الوقت الذي يستغرقه تازوباكتام للخروج من &nbsp;جسمك.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong><br />إذا كنتِ حاملًا أو مُرضعًا، أو تعتقدين بأنك قد تكونين حاملًا، استشيري طبيبك أو الصيدلي قبل تناول هذا الدواء. سوف ينصحك طبيبك إذا كان من الضروري أن تتناولي زِرباكسا خلال فترة الحمل.</p><p dir="RTL">إذا كنت ترضعين طفلك رضاعة طبيعية ، سيقوم طبيبك بإرشادك بشأن ما إذا كان يجب عليك التوقف عن الرضاعة الطبيعية أو التوقف عن أو تجنب العلاج بزِرباكسا، مع مراعاة فائدة الرضاعة الطبيعية للطفل والاستفادة من العلاج بالنسبة لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><br />قد يسبب زِرباكسا الدوخة، والتي يمكن أن تؤثر على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>زِرباكسا يحتوي على الصوديوم</strong></p><p dir="RTL">يحتوي هذا الدواء على 230 ملغم صوديوم (المكون الرئيسي للطهي/ملح الطعام) في كل فيال. وهذا يعادل 11.5٪ من الحد الأقصى الموصى بها من الحصة الغذائية اليومية من الصوديوم للبالغين. الفيال المعاد تشكيلها مع 10 مل من كلوريد الصوديوم 0.9٪ (ملح عادي) للحقن تحتوي على 265 ملغم صوديوم في كل فيال. وهذا يعادل 13.3٪ من الحد الأقصى الموصى بها من الحصة الغذائية اليومية من الصوديوم للبالغين.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">سيقوم طبيبك أو أخصائي الرعاية الصحية بإعطائك هذا الدواء بواسطة الحقن بالتسريب (بالتنقيط) داخل أحد أوردتك لمدة ساعة واحدة. تعتمد جرعة الدواء التي ستتلقاها على ما إذا كان لديك مشاكل في الكلى أم لا.</p><p dir="RTL">تعتمد الجرعة على نوع الالتهاب ، مكان الالتهاب في الجسم ومدى خطورة الالتهاب. سيقرر طبيبك الجرعة التي تحتاجها.</p><p dir="RTL"><u>البالغين</u></p><p dir="RTL">الجرعة الموصى بها من زِرباكسا هي1 غم من سيفتولوزان و 0.5 غم من تازوباكتام أو 2 ملغم سيفتولوزان و 1 غم تازوباكتام كل 8 ساعات، والتي تُعطى بواسطة الحقن بالتسريب في أحد أوردتك. (مباشرة في مجرى الدم).</p><p dir="RTL">يستمر العلاج مع زِرباكسا عادة ما بين 4 و 14 يومًا، اعتمادا على شدة وموضع العدوى وعلى كيفية استجابة جسمك للعلاج.</p><p dir="RTL"><u>الأطفال</u><u> </u><u>والمراهقين</u></p><p dir="RTL">&nbsp;الجرعة الموصى بها من زِرباكسا هي 20 مجم / كجم من سيفتولوزان و 20 مجم / كجم من تازوباكتام كل 8 ساعات ، والتي يتم إعطاؤها في أحد الأوردة (مباشرة في مجرى الدم ) . يجب ألا تتجاوز الجرعة 1 غرام من سيفتولوزان و 0,5 &nbsp;غرام من تازوباكتام. يستمر العلاج باستخدام زِرباكسا عادة ما بين 5 و 14 يوم ، اعتمادا على شدة العدوى وموقعها وكيفية استجابة جسمك للعلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>المرضى الذين يعانون من مشاكل في الكلى</u><br />قد يحتاج طبيبك إلى تقليل جرعة زِرباكسا أو تقليل عدد المرات التي يتم فيها إعطاؤك زِرباكسا. قد يرغب طبيبك أيضا في إجراء فحص لدمك للتأكد من حصولك على جرعة مناسبة، خاصة إذا كان عليك تلقي هذا الدواء لفترة طويلة.</p><p dir="RTL"><strong>إذا تلقيت من زِرباكسا أكثر مما يجب</strong></p><p dir="RTL">يتم إعطاء هذا المنتج من قبل الطبيب أو أحد المتخصصين في الرعاية الصحية، فمن المستبعد جدًّا أن يتم إعطاؤك الكثير من زِرباكسا. ومع ذلك، إذا كان لديك أي مخاوف يجب عليك اطلاع الطبيب أو الممرضة أو الصيدلي عليها على الفور.</p><p dir="RTL"><strong>إذا توقفت عن تلقي زِرباكسا</strong><br />إذا كنت تعتقد أنك لم تُعط إحدى جرعات زِرباكسا، أخبر طبيبك أو أخصائي الرعاية الصحية على الفور.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">كما هو الحال مع سائر الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، وإن كانت لا تحدث لدى جميع من يتناوله.</p><p dir="RTL"><strong>أخبر طبيبك على الفور إذا واجهت الأعراض التالية لأنّك قد تحتاج إلى علاج طبي عاجل حينها:</strong><br />- تورم مفاجئ في الشفتين، أو الوجه، أو الحلق أو اللسان؛ طفح جلدي شديد؛ وتورّم أو مشاكل في التنفس.<br />&nbsp;&nbsp; قد تكون هذه علامات على رد فعل تحسسي شديد (رد فعل تأقي) وقد تكون مهددة للحياة.<br />- الإسهال الذي يشتد مع العلاج أو لا يشفى أو&nbsp; البراز الذي يحتوي على الدم أو المخاط أثناء أو بعدالعلاج بزِرباكسا. في هذه الحالة، يجب أن تتجنب تناول الأدوية التي توقف أو تُبطىء من حركة الأمعاء.</p><p dir="RTL"><strong>البالغين الذين تم علاجهم من التهابات معقدة داخل المعدة والكلى والجهاز البولي</strong></p><p dir="RTL"><strong>الأعراض الجانبية الشائعة</strong> (قد تؤثر على ما يصل إلى 1 من بين 10 أشخاص):<br />الصداع، وآلام في المعدة، والإمساك، والإسهال، والغثيان، والتقيؤ، وزيادة في إنزيمات الكبد (يظهر في فحص الدم)، والطفح الجلدي، والحمى (ارتفاع في درجة الحرارة)، وانخفاض في ضغط الدم، وانخفاض في مستوى البوتاسيوم في الدم (يظهر في فحص الدم)، وزيادة في عدد نوع معين من خلايا الدم المعروفة باسم الصفائح الدموية، والدوخة، والقلق، وصعوبة في النوم، وردود الفعل في موضع الحقن بالتسريب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية غير الشائعة</strong> (قد تؤثر على ما يصل إلى 1 من بين 100 شخص):<br />التهاب الأمعاء الغليظة بسبب بكتيريا كلوستريديام ديفيسيل &quot;<em> </em><em>C. difficile </em>&quot;، والتهاب المعدة، وانتفاخ البطن، وعسر الهضم، وكثرة الغازات في المعدة أو الأمعاء، وانسداد الأمعاء، والالتهاب الفطري في الفم (السلاق الفموي)، والالتهاب المهبلي الفطري للإناث، والتهاب المسالك البولية الفطري، وارتفاع مستوى السكر في الدم (الجلوكوز) (يظهر في فحص الدم)، وانخفاض في مستويات المغنيسيوم (يظهر في فحص الدم)، وانخفاض في مستويات الفوسفات (يظهر في فحص الدم)، والسكتة الإقفارية (السكتة الدماغية الناجمة عن انخفاض تدفق الدم إلى الدماغ)، تهيج أو التهاب في الوريد عند موضع الحقن، تخثر وريدي (تجلط الدم في الوريد)، انخفاض عدد خلايا الدم الحمراء، الرجفان الأذيني (سرعة أو عدم انتظام ضربات القلب)، ضربات القلب السريعة، الذبحة الصدرية (ألم في الصدر أو الشعور بضيق، ضغط أو ثقل في الصدر)، طفح مصحوب بحكة أو تورمات جلدية، والشرى، ونتيجة إيجابية لفحص كومبس &quot; اختبار ضد الغلوبولين &quot;(اختبار للدم لتحقق من اجسام مضادة التي قد تهاجم خلايا الدم الحمراء)، مشاكل في الكلى، وأمراض الكلى، وضيق في التنفس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>أعراض جانبية</strong><strong> </strong><strong>إضافية</strong><strong> </strong><strong>لوحظت</strong><strong> </strong><strong>في</strong><strong> </strong><strong>الأطفال</strong><strong> </strong><strong>والمراهقين</strong><strong> </strong><strong>الذين تم علاجهم من</strong><strong> </strong><strong>الالتهابات</strong><strong> </strong><strong>المعقدة</strong><strong> </strong><strong>داخل</strong><strong> </strong><strong>البطن</strong><strong> </strong><strong>والكلى</strong><strong> </strong><strong>والجهاز</strong><strong> </strong><strong>البولي:</strong></p><p dir="RTL">الأعراض الجانبية الشائعة (قد تؤثر على ما يصل إلى 1 من بين 10 أشخاص):</p><p dir="RTL">&nbsp;زيادة الشهية ، وانخفاض عدد خلايا الدم البيضاء ، و تغير في التذوق</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>البالغين الذين تم علاجهم من التهاب الرئة</strong></p><p dir="RTL"><strong>الأعراض الجانبية الشائعة</strong> (قد تؤثر على ما يصل إلى 1 من بين 10 أشخاص):</p><p dir="RTL">التهاب الأمعاء الغليظة بسبب بكتيريا كلوستريديام ديفيسيل &quot; <em>C. difficile </em>&quot;والإسهال والقيء وارتفاع إنزيمات الكبد ) اختبارات الدم (</p><p dir="RTL">&nbsp;<strong>ا</strong><strong>لأعراض الجانبية غير الشائعة</strong> (قد تؤثر على ما يصل إلى 1 من بين 100 شخص):</p><p dir="RTL">التهاب بسبب بكتيريا كلوستريديام ديفيسيل &quot; <em>C. difficile </em>&quot;<em> </em>، نتيجة فحص إيجابية لوجود <em>C. difficile</em> في البراز، نتيجة فحص إيجابية لاختبار الدم لتحقق من اجسام مضادة التي قد تهاجم خلايا الدم الحمراء.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong><br />إذا تعرّضت لأي أعراض جانبية، تحدث مع طبيبك أو الصيدلي. ويشمل ذلك أي أعراض جانبية محتملة غير مدرجة في هذه النشرة. یمکنك أیضا الإبلاغ عن الأعراض الجانبیة مباشرة عن طریق &quot; المرکز الوطني للتيقّظ والسلامة الدوائية، التابع للهيئة العامة للغذاء والدواء &quot; من خلال الإبلاغ عن الأعراض الجانبیة، یمکنك المساعدة في تقدیم المزید من المعلومات حول سلامة الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد تاریخ إنتهاء الصلاحیة المُدون علی الفيال والعلبة بعد &quot;EXP&quot;.</p><p dir="RTL">الزجاجات غير المفتوحة: احفظها في الثلاجة (2 - 8 درجة مئوية).</p><p dir="RTL">احفظ القارورة داخل علبتها الخارجية من أجل حماية المنتج من الضوء.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي. أي منتج طبي غير مستعمل أو نفايات يجب التخلص منها وفقا للمتطلبات المحلية. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي زِرباكسا</strong></p><p dir="RTL">- المواد الفعالة هي سيفتولوزان و تازوباكتام.<br />- تحتوي كل فيال على كبريتات سيفتولوزان أي ما يعادل 1 غم سيفتولوزان و تازوباكتام الصوديوم أي ما يعادل 0.5 غم تازوباكتام. للجرعات أعلى من 1 غم سيفتولوزان و 0.5 غم تازوباكتام، يتم إستخدام 2 فيال .</p><p dir="RTL">- المواد الأخرى الغير فعّالة هي: كلوريد الصوديوم ،إل- أرجينين ، وحامض الستريك اللامائي .</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو زِرباكسا وما هي محتويات العبوة</strong><br />زِرباكسا هو مسحوق لونه يتأرجح ما بين الأبيض المائل إلى الأصفر قليلا مُعد للحقن (مسحوق مُركّز) ويتوفر في قارورة.</p><p dir="RTL">يتوفر زِرباكسا في زجاجات سعتها 20 مل مصنوعة من الزجاج الشفاف نوع 1 مع سدادة (المطاط بروموبوتيل) وغطاء يُرفع بالضغط على حافته من الأسفل إلى الأعلى.</p><p dir="RTL">تحتوي كل علبة على 10 زجاجات .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق </strong><br />ميرك شارب ودوهم المحدودة<br />طريق هيرتفورد ، هوديسدون<br />هيرتفوردشاير أي أن ١١ ٩ بي يو<br />المملكة المتحدة</p><p dir="RTL"><strong>الشركة الصانعة </strong><br />شركة ستيري-فارما، ذات مسؤولية محدودة<br />429 شارع ويست ستريت، نيويورك، سيراكوس، 13202، الولايات المتحدة الأمريكية</p><p dir="RTL">فاريفا ميرابيل - فرنسا الطريق دي مارسات ريوم ، كليرمون فيراند سيديكس 9 ، 63963 فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت الموافقة على هذه النشرة بتاريخ {يوليو 2022}.
للإبلاغ عن الأعراض الجانبية:
•	المملكة العربية السعودية:
المركز الوطني للتيقظ والسلامة الدوائية
للاتصال باالهيئة العامة للغذاء والدواء: 1999
البريد الالكتروني: npc.drug@sfda.gov.sa
الموقع الالكتروني: https://ade.sfda.gov.sa
•	دول الخليج الأخرى
الرجاء الاتصال بالمؤسسات والهيئات الوطنية في كل دولة.



(إنّ هذا الدواء)
- الدواء مستحضر يؤثر على صحتك واستهلاكه خلافًا للتعليمات يعرضك للخطر
- اتبع بدقة وصفة الطبيب وطريقة الاستعمال المنصوص عليها وتعليمات الصيدلي الذي صرفها لك
- إن الطبيب والصيدلي هما الخبيران بالدواء وبنفعه وضرره
- لا تقطع مدة العلاج المحددة لك من تلقاء نفسك
- لا تكرر صرف الدواء بدون استشارة الطبيب
- لا تترك الأدوية في متناول أيدي الأطفال

مجلس وزراء الصحة العرب
واتحاد الصيادلة العرب
تمت الموافقة على هذه النشرة من قبل الهيئة العامة للغذاء والدواء بالمملكة العربية السعودية

.......................................................................................................
المعلومات التالية موجهة لأخصائيي الرعاية الصحيّة فقط:
إعداد المحاليل
الفيال (القارورة) مُعدة لاستخدام واحد فقط.
يجب اتباع تقنية التعقيم في إعداد محلول الحقن بالتسريب.
إعداد الجرعات
يتم إعادة تشكيل مسحوق الحقن على هيئة محلول باضافة 10 مل من الماء المُخصّص للحقن أو محلول كلوريد الصوديوم 9  ملغم/مل (0.9٪) لكل قارورة؛ ومن ثمّ يجب رجّ القارورة بلطف كي يذوب المسحوق. الحجم النهائي الناتج بعد إعادة تشكيل مسحوق الحقن على هيئة محلول هو حوالي 11.4 مل. ويبلغ تركيز المحلول الناتج حوالي 132 ملغم /مل (88 ملغم /مل من سيفتولوزان و 44 ملغم /مل من تازوباكتام).
تنبيه: المحلول الناتج بعد إعادة تشكيل مسحوق الحقن غير مُعد للحقن المباشر.
محلول زِرباكسا المُعد للحقن بالتسريب شفاف يتأرجح في لونه بين عديم اللون إلى الأصفر قليلا.
 الاختلافات في اللون ضمن هذا النطاق لا تؤثر على قوة المنتج.

إنظر البند 4.2 "ملخص خصائص المستحضر" للجرعة الموصى بها  من زِرباكسا بناءا على الغرض العلاجي  ووظائف الكلى.  طريقة تحضير كل جرعة موضحة أدناه.

لإعداد جرعات البالغين في كيس التسريب:

لإعداد جرعة 2  غرام سيفتولوزان/  1 غرام تازوباكتام: إسحب المحتويات بأكملها من قارورتان أعيد تشكيلهما (حوالي 11.4 مل لكل قارورة) باستخدام حقنة وإضافتها إلى كيس ضخ يحتوي على 100 مل من كلوريد الصوديوم 0.9٪ للحقن (المحلول الملحي الفسيولوجي) أو 5٪ جلوكوز للحقن.
لإعداد جرعة1.5 غرام سيفتولوزان/  0.75  غرام تازوباكتام: إسحب المحتويات بأكملها من فيال واحدة أعيد تشكلهما (حوالي 11.4 مل لكل قارورة) و 5.7 مل من فيال أخرى أعيد تشكلهما  و قم بإضافتها إلى كيس ضخ يحتوي على 100 مل من كلوريد الصوديوم 0.9٪ للحقن (المحلول الملحي الفسيولوجي) أو 5٪ جلوكوز للحقن.
لإعداد جرعة 1 جرام سيفتولوزان / 0.5 جرام تازوباكتام: اسحب محتويات القارورة (حوالي 11.4 مل) بعد إعادة تشكيل مسحوق الحقن باستخدام محقنة وقم بإضافته إلى كيس محلول الحقن بالتسريب المُخفِّف الذي يحتوي على 100 مل من محلول 0.9٪ كلوريد الصوديوم (المحلول الملحي الفسيولوجي) أو 5٪ الجلوكوز.

لإعداد جرعة تتكون من 500 ملغم سيفتولوزان / 250 ملغم تازوباكتام: اسحب 5.7 مل من محتويات القارورة بعد إعادة تشكيل مسحوق الحقن باستخدام محقنة وقم بإضافته إلى كيس محلول الحقن بالتسريب الذي يحتوي على 100 مل من  محلول 0.9٪ كلوريد الصوديوم (المحلول الملحي الفسيولوجي) أو 5٪ الجلوكوز.

لإعداد جرعة تتكون من 300 ملغم سيفتولوزان / 150 ملغم تازوباكتام: اسحب 3.5 مل من محتويات القارورة بعد إعادة تشكيل مسحوق الحقن باستخدام محقنة وقم بإضافته إلى كيس محلول الحقن بالتسريب الذي يحتوي على 100 مل من  محلول 0.9٪ كلوريد الصوديوم (المحلول الملحي الفسيولوجي) أو 5٪ الجلوكوز.

لإعداد جرعة تتكون من 250 ملغم سيفتولوزان / 125 ملغم تازوباكتام: اسحب 2.9 مل من محتويات القارورة بعد إعادة تشكيل مسحوق الحقن باستخدام محقنة وقم بإضافته إلى كيس محلول الحقن بالتسريب الذي يحتوي على 100 مل من  محلول 0.9٪ كلوريد الصوديوم (المحلول الملحي الفسيولوجي) أو 5٪ الجلوكوز.
لإعداد جرعة تتكون من 100 ملغم سيفتولوزان / 50 ملغم تازوباكتام: اسحب 1.2 مل من محتويات القارورة بعد إعادة تشكيل مسحوق الحقن باستخدام محقنة وقم بإضافته إلى كيس محلول الحقن بالتسريب الذي يحتوي على 100 لل من  محلول 0.9٪ كلوريد الصوديوم (المحلول الملحي الفسيولوجي) أو 5٪ الجلوكوز.

تعليمات لإعداد جرعات الأطفال في كيس التسريب أو في حقنة التسريب:
 ملاحظة: يصف الإجراء التالي خطوات تحضير 100 مل من محلول المخزون بتركيز نهائي قدره 10 ملغم/مل سيفتولوزان / 5 ملغ/مل تازوباكتام. 
يعتمد حجم هذا الذي سيتم إعطاؤه للطفل على حساب الجرعة المناسبة بناء على وزن المريض (إنظر البند 4.2 "ملخص خصائص المستحضر" )  طريقة تحضير كل جرعة موضحة أدناه (الخطوات والحسابات التفصيلية).
1.	تحضير محلول ( 100 مل من سيفتولوز 10 ملغ/مل/5 ملغ/مل تازوباكتام ): 
اسحب كامل محتويات القارورة المعاد تشكيلها  (حوالي 11,4  مل)  باستخدام حقنة وأضفها إلى كيس تسريب يحتوي على 89 مل من كلوريد الصوديوم 0,9 ٪ المخصص للحقن  (محلول ملحي عادي ) أو حقنة جلوكوز 5٪.
2.	تحضير الحجم المطلوب من محلول التسريب: 
a)	احسب الكمية المناسبة من زِرباكسا بالملغ لاعطاء الجرعة المطلوبة للطفل المريض. بناء على هذه الجرعة بالمجم ، احسب قم بحساب الحجم المناسب لمحلول 10 مجم / مل سيفتولوزان / 5 مجم / مل من محلول التازوباكتام المراد إعطاؤه. راجع الجدول رقم 1 أدناه لتأكيد الحسابات.
لاحظ أن الجدول لا يشمل جميع الجرعات المحسوبة الممكنة ولكن يمكن استخدامه لتقدير الحجم التقريبي للتحقق من الحساب.
b)	انقل الحجما المحسوب بشكل مناسب من المحلول إلى كيس تسريب أو حقنة تسريب بحجم مناسب. القيم المبينة في الجدول رقم 1 تقريبية ، وقد يكون من الضروري التقريب إلى أقرب علامة تخرج لحقنة ذات حجم مناسب لأحجام أصغر.
الجدول رقم 1 : تحضير زيرباكسا للأطفال المرضى (من عمر  الولادة* إلى أقل من 18 عام) من محلول 100 مل من سيفتولوزان 10 ملغ/مل / 5 ملغ/مل تازوباكتام
جرعة زيرباكسا
 (ملغم / كغم)	الوزن (كجم)
	الكمية المحسوبة من سيفتولوزان (ملغ)
	الكمية المحسوبة من تازوباكتام (ملغ)	حجم محلول المخزون المراد اعطائه للمريض (مل)
20 ملغ/كغ سيفتولوزان / 10 ملغ/كغ تازوباكتام**	50 وما فوق	1000	500	100
	40	800	400	80
	30	600	300	60
	20	400	200	40
	15	300	150	30
	10	200	100	20
	5	100	50	10
	3	60	30	6
	1,5	30	15	3

* يعرف بأنه  < 32 أسبوعا من عمر الحمل و ≤  7 ايام بعد الولادة. 
** يجب ألا يتجاوز وزن الأطفال < 50 كجم والذين لديهم  معدل الترشيح الكبيبي المقدر < 50مل / دقيقة / 1,73 م2  الجرعة القصوى البالغة يجب ان لا تتجاوز1 جم سيفتولوزان / 0,5 جم تازوباكتام.
من وجهة النظر علم الأحياء الدقيقة (الميكروبيولوجية)، يجب استخدام المنتج الطبي فورًا بعد إعادة تشكيل المسحوق على هيئة محلول. وإذا لم يُستخدم على الفور، فإنّ أوقات وظروف التخزين المُتبعة أثناء الاستخدام هي من مسؤولية المستخدم، وعادة لا تكون تلك الفترة أطول من 24 ساعة في درجة حرارة 2 إلى 8 درجة مئوية .ما لم يتم إعادة تشكيل المسحوق/التخفيف في ظروف مُعقّمة مراقبة وموثقة. 

سيفتولوزان ، أحد المكونات الفعالة، ، قد يكون له آثار ضارة إذا وصل إلى البيئة المائية. لا ترمي أي منتج طبي غير مستخدم أو مواد نفايات عن طريق مياه الصرف الصحي. وينبغي التخلص من أي منتج طبي أو مواد نفايات غير مستخدمة وفقا للمتطلبات المحلية. وستساعد هذه التدابير على حماية البيئة.يجب التخلص من أيّ منتج طبي أو نفايات طبية غير مستخدمة وفقًا للمتطلبات المحلية.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zerbaxa 1 g/0.5 g powder for concentrate for solution for infusion
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each vial contains ceftolozane sulfate equivalent to 1 g ceftolozane and tazobactam sodium equivalent to 0.5 g tazobactam.

After reconstitution with 10 mL diluent, the total volume of the solution in the vial is 11.4 mL, which contains 88 mg/mL of ceftolozane and 44 mg/mL of tazobactam.

Excipient with known effect

Each vial contains 10 mmol (230 mg) of sodium.

When the powder is reconstituted with 10 mL of sodium chloride 9 mg/mL (0.9%) solution for injection, the vial contains 11.5 mmol (265 mg) of sodium.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Powder for concentrate for solution for infusion (powder for concentrate).

White to yellowish powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:37.35pt; text-indent:-26.65pt"><!--[if !supportLists]--></p><p>&nbsp;</p><p>Zerbaxa is indicated for the treatment of the following infections in adult and paediatric patients (see sections&nbsp;4.2 and&nbsp;5.1):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated intra‑abdominal infections (see section&nbsp;4.4);</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acute pyelonephritis;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Complicated urinary tract infections (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Zerbaxa is also indicated for the treatment of the following infection in adult patients (18&nbsp;years or older) (see section&nbsp;5.1):</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hospital-acquired pneumonia (HAP), including ventilator‑associated pneumonia (VAP).</p><p>&nbsp;</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><u>&nbsp;</u></p><p>The recommended intravenous dose regimen for adult patients with creatinine clearance &gt;&nbsp;50&nbsp;mL/min is shown by infection type in Table&nbsp;1.</p><p><strong>&nbsp;</strong></p><p><strong>Table 1: Intravenous dose of Zerbaxa by type of infection in adult patients (18&nbsp;years or older)</strong><strong> with creatinine clearance* &gt;&nbsp;50&nbsp;mL/min</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>Type of infection</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Infusion time</strong></p></td><td style="vertical-align:top"><p><strong>Duration of treatment</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Complicated intra‑abdominal infection**</p></td><td style="vertical-align:top"><p>1&nbsp;g ceftolozane / 0.5&nbsp;g tazobactam</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>1&nbsp;hour</p></td><td style="vertical-align:top"><p>4‑14&nbsp;days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infection</p><p>Acute pyelonephritis</p></td><td style="vertical-align:top"><p>1&nbsp;g ceftolozane / 0.5&nbsp;g tazobactam</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>1&nbsp;hour</p></td><td style="vertical-align:top"><p>7&nbsp;days</p></td></tr><tr><td style="vertical-align:top"><p>Hospital-acquired pneumonia, including ventilator‑associated pneumonia***</p></td><td style="vertical-align:top"><p>2&nbsp;g ceftolozane / 1&nbsp;g tazobactam</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>1&nbsp;hour</p></td><td style="vertical-align:top"><p>8‑14&nbsp;days</p></td></tr></tbody></table><p>*Creatinine clearance estimated using Cockcroft-Gault formula.</p><p>**To be used in combination with metronidazole when anaerobic pathogens are suspected.</p><p>***To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process.</p><p>&nbsp;</p><p>The recommended intravenous dose regimen for paediatric patients with estimated glomerular filtration rate (eGFR) &gt;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> is shown by infection type in Table&nbsp;2.</p><p>&nbsp;</p><p>Table 2: Intravenous dose of Zerbaxa by type of infection in paediatric patients (from birth* to below 18&nbsp;years of age) with eGFR** &gt;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Type of infection</strong></p></td><td style="vertical-align:top"><p><strong>Dose</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Infusion time</strong></p></td><td style="vertical-align:top"><p><strong>Duration of treatment</strong></p></td></tr><tr><td style="vertical-align:top"><p>Complicated intra-abdominal infection***</p></td><td style="vertical-align:top"><p>20&nbsp;mg/kg ceftolozane / 10&nbsp;mg/kg tazobactam up to a maximum dose of 1&nbsp;g ceftolozane / 0.5&nbsp;g tazobactam****</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>1&nbsp;hour</p></td><td style="vertical-align:top"><p>5-14&nbsp;days*****</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infection</p><p>Acute pyelonephritis</p></td><td style="vertical-align:top"><p>20&nbsp;mg/kg ceftolozane / 10&nbsp;mg/kg tazobactam up to a maximum dose of 1&nbsp;g ceftolozane / 0.5&nbsp;g tazobactam****</p></td><td style="vertical-align:top"><p>Every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>1&nbsp;hour</p></td><td style="vertical-align:top"><p>7-14&nbsp;days*****</p></td></tr></tbody></table><p>*Defined as &gt;&nbsp;32&nbsp;weeks gestational age and &ge;&nbsp;7&nbsp;days postnatal.</p><p>**eGFR estimated using Bedside Schwartz equation.</p><p>***To be used in combination with metronidazole when anaerobic pathogens are suspected.</p><p>****Children weighing &gt;&nbsp;50&nbsp;kg should not exceed the maximum dose of 1&nbsp;g ceftolozane&nbsp;/&nbsp;0.5&nbsp;g tazobactam.</p><p>*****The total treatment duration shown may include intravenous Zerbaxa followed by appropriate oral therapy.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>&nbsp;</em></p><p><em>Elderly (&ge;&nbsp;</em><em>65&nbsp;years of age)</em></p><p>No dose adjustment is necessary for the elderly based on age alone (see section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>In patients with mild renal impairment (estimated creatinine clearance &gt;&nbsp;50&nbsp;mL/min), no dose adjustment is necessary (see section&nbsp;5.2).</p><p>&nbsp;</p><p>In adult patients with moderate or severe renal impairment, and in adult patients with end stage renal disease on haemodialysis, the dose should be adjusted as listed in Table&nbsp;3 (see sections&nbsp;5.1 and 6.6).</p><p>&nbsp;</p><p><strong>Table 3: Recommended intravenous dose regimens for Zerbaxa in adult patients (18&nbsp;years or older)</strong> <strong>with creatinine clearance* &le;&nbsp;50&nbsp;mL/min </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Estimated creatinine clearance (mL/min)*</strong></p></td><td style="vertical-align:top"><p><strong>Complicated intra‑abdominal infections, complicated urinary tract infections, and acute pyelonephritis**</strong></p></td><td style="vertical-align:top"><p><strong>Hospital-acquired pneumonia, including ventilator‑associated pneumonia**</strong></p></td></tr></thead><tbody><tr><td><p>30 to 50</p></td><td><p>500&nbsp;mg ceftolozane / 250&nbsp;mg tazobactam intravenously every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>1&nbsp;g ceftolozane / 0.5&nbsp;g tazobactam intravenously every 8&nbsp;hours</p></td></tr><tr><td><p>15 to 29</p></td><td><p>250&nbsp;mg ceftolozane / 125&nbsp;mg tazobactam intravenously every 8&nbsp;hours</p></td><td style="vertical-align:top"><p>500&nbsp;mg ceftolozane / 250&nbsp;mg tazobactam intravenously every 8&nbsp;hours</p></td></tr><tr><td><p>End stage renal disease on haemodialysis</p></td><td><p>A single loading dose of 500&nbsp;mg ceftolozane / 250&nbsp;mg tazobactam followed after 8&nbsp;hours by a 100&nbsp;mg ceftolozane / 50&nbsp;mg tazobactam maintenance dose administered every 8&nbsp;hours for the remainder of the treatment period (on haemodialysis days, the dose should be administered at the earliest possible time following completion of haemodialysis)</p></td><td style="vertical-align:top"><p>A single loading dose of 1.5&nbsp;g ceftolozane / 0.75&nbsp;g tazobactam followed after 8&nbsp;hours by a 300&nbsp;mg ceftolozane / 150&nbsp;mg tazobactam maintenance dose administered every 8&nbsp;hours for the remainder of the treatment period (on haemodialysis days, the dose should be administered at the earliest possible time following completion of haemodialysis)</p></td></tr></tbody></table><p>*Creatinine clearance estimated using Cockcroft‑Gault formula.</p><p>**All doses of Zerbaxa are administered intravenously over 1&nbsp;hour and are recommended for all indications. The duration of treatment should follow the recommendations in Table&nbsp;1.</p><p>&nbsp;</p><p>There is insufficient information to recommend a dose regimen for paediatric patients with moderate or severe renal impairment (eGFR &le;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) or end stage renal disease (see sections&nbsp;5.1 and 5.2).</p><p><em>&nbsp;</em></p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary in patients with hepatic impairment (see section&nbsp;5.2)<em>.</em></p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>The safety and efficacy of ceftolozane/tazobactam in children and adolescents below 18&nbsp;years of age have not yet been established for the treatment of hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP).</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>Zerbaxa is to be administered by intravenous infusion over a 1&nbsp;hour period for all doses.</p><p>&nbsp;</p><p><em>Precautions to be taken before handling or administering the product</em></p><p>See section&nbsp;6.2 for incompatibilities.</p><p>&nbsp;</p><p>See section&nbsp;6.6 for instructions on reconstitution and dilution of the medicinal product before administration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
-	Hypersensitivity to the active substances or to any of the excipients listed in section 6.1;
-	Hypersensitivity to any cephalosporin antibacterial agent;
-	Severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta lactam antibacterial agent (e.g., penicillins or carbapenems).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity reactions</u></p><p>Serious and occasionally fatal hypersensitivity (anaphylactic) reactions are possible (see sections&nbsp;4.3 and 4.8). If a severe allergic reaction occurs during treatment with ceftolozane/tazobactam, the medicinal product should be discontinued and appropriate measures taken.</p><p>&nbsp;</p><p>Patients who have a history of hypersensitivity to cephalosporins, penicillins or other beta-lactam antibacterial agents may also be hypersensitive to ceftolozane/tazobactam.</p><p>&nbsp;</p><p>Ceftolozane/tazobactam is contraindicated in patients with a history of hypersensitivity to ceftolozane, tazobactam, or cephalosporins (see section&nbsp;4.3).</p><p>&nbsp;</p><p>Ceftolozane/tazobactam is also contraindicated in patients with severe hypersensitivity (e.g., anaphylactic reaction, severe skin reaction) to any other type of beta‑lactam antibacterial agent (e.g., penicillins or carbapenems) (see section&nbsp;4.3).</p><p>&nbsp;</p><p>Ceftolozane/tazobactam should be used with caution in patients with a history of any other type of hypersensitivity reaction to penicillins or other beta‑lactam antibacterial agents.</p><p><strong>&nbsp;</strong></p><p><u>Effect on renal function</u></p><p>&nbsp;</p><p>A decline in renal function has been seen in adult patients receiving ceftolozane/tazobactam.</p><p>&nbsp;</p><p><u>Impaired renal function</u></p><p>&nbsp;</p><p>The ceftolozane/tazobactam dose should be adjusted based on renal function (see section&nbsp;4.2, Table&nbsp;3).</p><p>&nbsp;</p><p>In clinical trials of complicated intra<strong>‑</strong>abdominal infections and complicated urinary tract infections, including pyelonephritis, the efficacy of ceftolozane/tazobactam was lower in adult patients with moderate renal impairment compared with those with normal or mildly impaired renal function at baseline.</p><p>&nbsp;</p><p>Patients with renal impairment at baseline should be monitored frequently for any changes in renal function during treatment and the dose of ceftolozane/tazobactam should be adjusted as necessary.</p><p><u>Limitations of the clinical data</u></p><p>Patients who were immunocompromised, patients with severe neutropenia, and patients with end stage renal disease on haemodialysis were excluded from clinical trials.</p><p><em>Complicated intra-abdominal infections</em></p><p>In a trial in adult patients with complicated intra‑abdominal infections, the most common diagnosis was appendiceal perforation or peri‑appendiceal abscess (420/970 [43.3%]&nbsp;patients), of which 137/420 (32.6%) had diffuse peritonitis at baseline. Approximately 82% of all patients in the trial had APACHE II (Acute Physiology and Chronic Health Evaluation II) scores of &lt;&nbsp;10 and 2.3% had bacteraemia at baseline. In the clinically evaluable (CE) patients, the clinical cure rates for ceftolozane/tazobactam were 95.9% in 293&nbsp;patients aged less than 65&nbsp;years and 87.8% in 82&nbsp;patients aged 65&nbsp;years or more.</p><p>&nbsp;</p><p><em>Complicated urinary tract infections</em></p><p>Clinical efficacy data in adult patients with complicated lower urinary tract infection are limited. In a randomised active‑controlled trial 18.2% (126/693) of microbiologically evaluable (ME) patients had complicated lower urinary tract infection, including 60/126&nbsp;patients who were treated with ceftolozane/tazobactam. One of these 60&nbsp;patients had bacteraemia at baseline.</p><p>&nbsp;</p><p><em><u>Clostridioides difficile</u></em><u>‑associated diarrhoea</u></p><p>Antibacterial-associated colitis and pseudomembranous colitis have been reported with ceftolozane/tazobactam (see section&nbsp;4.8). These types of infection may range in severity from mild to life-threatening. Therefore, it is important to consider this diagnosis in patients who present with diarrhoea during or subsequent to the administration of ceftolozane/tazobactam. In such circumstances, the discontinuation of therapy with ceftolozane/tazobactam and the use of supportive measures together with the administration of specific treatment for <em>Clostridioides difficile </em>should be considered.</p><p>&nbsp;</p><p><u>Non-susceptible micro‑organisms</u></p><p>The use of ceftolozane/tazobactam may promote the overgrowth of non‑susceptible micro‑organisms. If super infection occurs during or following treatment, appropriate measures should be taken.</p><p>&nbsp;</p><p>Ceftolozane/tazobactam is not active against bacteria that produce beta‑lactamase enzymes which are capable of both degrading ceftolozane and not inhibited by the tazobactam component (see section&nbsp;5.1).</p><p><u>Direct antiglobulin test (Coombs test) seroconversion and potential risk of haemolytic anaemia</u></p><p>&nbsp;</p><p>The development of a positive direct antiglobulin test (DAGT) may occur during treatment with ceftolozane/tazobactam (see section&nbsp;4.8). In clinical studies, there was no evidence of haemolysis in patients who developed a positive DAGT on treatment.</p><p>&nbsp;</p><p><u>Sodium content</u></p><p>Ceftolozane/tazobactam contains 230&nbsp;mg sodium per vial, equivalent to 11.5% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult. The reconstituted vial with 10&nbsp;mL of 0.9% sodium chloride (normal saline) for injection contains 265&nbsp;mg sodium per vial, equivalent to 13.3% of the WHO recommended maximum daily intake of 2&nbsp;g sodium for an adult.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No significant medicinal product interactions are anticipated between ceftolozane/tazobactam and substrates, inhibitors, and inducers of cytochrome P450 enzymes (CYPs) based on <em>in vitro</em> and <em>in vivo</em> studies.</p><p>&nbsp;</p><p><em>In vitro</em> studies demonstrated that ceftolozane, tazobactam and the M1 metabolite of tazobactam did not inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, or CYP3A4 and did not induce CYP1A2, CYP2B6, or CYP3A4 at therapeutic plasma concentrations.</p><p>&nbsp;</p><p>Ceftolozane and tazobactam were not substrates for P‑gp or BCRP, and tazobactam was not a substrate for OCT2, <em>in vitro</em> at therapeutic plasma concentrations. <em>In vitro</em> data indicate that ceftolozane did not inhibit P‑gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, MRP, BSEP, OAT1, OAT3, MATE1, or MATE2‑K <em>in vitro</em> at therapeutic plasma concentrations. <em>In vitro</em> data indicate that neither tazobactam nor the tazobactam metabolite M1 inhibit P‑gp, BCRP, OATP1B1, OATP1B3, OCT1, OCT2, or BSEP transporters at therapeutic plasma concentrations.</p><p>&nbsp;</p><p>Tazobactam is a substrate for OAT1 and OAT3. <em>In vitro</em>, tazobactam inhibited human OAT1 and OAT3 transporters with IC<sub>50</sub> values of 118 and 147&nbsp;mcg/mL, respectively. Co‑administration of ceftolozane/tazobactam with OAT1 and OAT3 substrate furosemide in a clinical study did not significantly increase furosemide plasma exposures (geometric mean ratios of 0.83 and 0.87 for C<sub>max</sub> and AUC, respectively). However, active substances that inhibit OAT1 or OAT3 (e.g., probenecid) may increase tazobactam plasma concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no data on the use of ceftolozane/tazobactam in pregnant women. Tazobactam crosses the placenta. It is not known if ceftolozane crosses the placenta.</p><p>&nbsp;</p><p>Animal studies with tazobactam have shown reproductive toxicity (see section&nbsp;5.3) without evidence of teratogenic effects. Studies with ceftolozane in mice and rats have not shown evidence of reproductive toxicity or teratogenicity. Ceftolozane administered to rats during pregnancy and breast-feeding was associated with a decrease in auditory startle response in postnatal day (PND) 60&nbsp;male pups (see section&nbsp;5.3).</p><p>&nbsp;</p><p>Zerbaxa should only be used during pregnancy if the expected benefit outweighs the possible risks to the pregnant woman and foetus.</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether ceftolozane and tazobactam are excreted in human milk. A risk to newborns/infants cannot be excluded. A decision must be made whether to discontinue breast‑feeding or to discontinue/abstain from Zerbaxa therapy taking into account the benefit of breast‑feeding for the child and the benefit of therapy for the woman.</p><p><u>Fertility</u></p><p>&nbsp;</p><p>The effects of ceftolozane and tazobactam on fertility in humans have not been studied. Fertility studies in rats showed no effect on fertility and mating after intraperitoneal administration of tazobactam or intravenous administration of ceftolozane (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zerbaxa may have a minor influence on the ability to drive and use machines. Dizziness may occur following administration of Zerbaxa (see section&nbsp;4.8).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><u>&nbsp;</u></p><p>Zerbaxa was evaluated in Phase&nbsp;3 comparator‑controlled clinical trials of complicated intra‑abdominal infections and complicated urinary tract infections (including pyelonephritis) in adult patients.</p><p>&nbsp;</p><p>The most common adverse reactions (&ge;&nbsp;3% in pooled Phase&nbsp;3 trials of complicated intra‑abdominal infections and complicated urinary tract infections, including pyelonephritis) occurring in patients receiving Zerbaxa were nausea, headache, constipation, diarrhoea, and pyrexia and were generally mild or moderate in severity.</p><p>&nbsp;</p><p>Zerbaxa was evaluated in a Phase&nbsp;3 comparator‑controlled clinical trial of adult patients with hospital-acquired pneumonia, including ventilator‑associated pneumonia.</p><p><u>&nbsp;</u></p><p>The most common adverse reactions (&ge;&nbsp;5% in a Phase&nbsp;3 trial of hospital-acquired pneumonia, including ventilator‑associated pneumonia) occurring in patients receiving Zerbaxa were diarrhoea, alanine aminotransferase increased, and aspartate aminotransferase increased and were generally mild or moderate in severity.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The following adverse reactions have been identified during adult clinical trials with Zerbaxa. Adverse reactions are classified according to MedDRA system organ class and frequency. Frequency categories are derived according to the following conventions: common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100) (see Table&nbsp;4).</p><p>&nbsp;</p><p><strong>Table 4: Adverse reactions identified during adult clinical trials with ceftolozane/tazobactam</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><thead><tr><td><p><strong>System organ class</strong></p></td><td><p><strong>Common </strong></p><p><strong>(&ge;&nbsp;1/100 to &lt;&nbsp;1/10)</strong></p></td><td><p><strong>Uncommon </strong></p><p><strong>(&ge;&nbsp;1/1&nbsp;000 to &lt;&nbsp;1/100)</strong></p></td></tr></thead><tbody><tr><td><p>Infections and infestations</p></td><td><p><em>Clostridioides difficile</em> colitis<sup>2</sup></p></td><td><p>Candidiasis including oropharyngeal and vulvovaginal<sup>1</sup>, <em>Clostridioides difficile</em> colitis<sup>1</sup>, fungal urinary tract infection<sup>1</sup>, <em>Clostridioides difficile</em> infection<sup>2</sup></p></td></tr><tr><td><p>Blood and the lymphatic system disorders</p></td><td><p>Thrombocytosis<sup>1</sup></p></td><td><p>Anaemia<sup>1</sup></p></td></tr><tr><td><p>Metabolism and nutrition disorders</p></td><td><p>Hypokalemia<sup>1</sup></p></td><td><p>Hyperglycaemia<sup>1</sup>, hypomagnesaemia<sup>1</sup>, hypophosphataemia<sup>1</sup></p></td></tr><tr><td><p>Psychiatric disorders</p></td><td><p>Insomnia<sup>1</sup>, anxiety<sup>1</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Nervous system disorders</p></td><td><p>Headache<sup>1</sup>, dizziness<sup>1</sup></p></td><td><p>Ischemic stroke<sup>1</sup></p></td></tr><tr><td><p>Cardiac disorders</p></td><td><p>&nbsp;</p></td><td><p>Atrial fibrillation<sup>1</sup>, tachycardia<sup>1</sup>, angina pectoris<sup>1</sup></p></td></tr><tr><td><p>Vascular disorders</p></td><td><p>Hypotension<sup>1</sup></p></td><td><p>Phlebitis<sup>1</sup>, venous thrombosis<sup>1</sup></p></td></tr><tr><td><p>Respiratory, thoracic, and mediastinal disorders</p></td><td><p>&nbsp;</p></td><td><p>Dyspnoea<sup>1</sup></p></td></tr><tr><td><p>Gastrointestinal disorders</p></td><td><p>Nausea<sup>1</sup>, diarrhoea<sup>3</sup>, constipation<sup>1</sup>, vomiting<sup>3</sup>, abdominal pain<sup>1</sup></p></td><td><p>Gastritis<sup>1</sup>, abdominal distension<sup>1</sup>, dyspepsia<sup>1</sup>, flatulence<sup>1</sup>, ileus paralytic<sup>1</sup></p></td></tr><tr><td><p>Skin and subcutaneous tissue disorders</p></td><td><p>Rash<sup>1</sup></p></td><td><p>Urticaria<sup>1</sup></p></td></tr><tr><td><p>Renal and urinary disorders</p></td><td><p>&nbsp;</p></td><td><p>Renal impairment<sup>1</sup>, renal failure<sup>1</sup></p></td></tr><tr><td><p>General disorders and administration site conditions</p></td><td><p>Pyrexia<sup>1</sup>, infusion site reactions<sup>1</sup></p></td><td><p>&nbsp;</p></td></tr><tr><td><p>Investigations</p></td><td><p>Alanine aminotransferase increased<sup>3</sup>, aspartate aminotransferase increased<sup>3</sup>, transaminases increased<sup>2</sup>, liver function test abnormal<sup>2</sup>, blood alkaline phosphatase increased<sup>2</sup>, gamma-glutamyltransferase increased<sup>2</sup></p></td><td><p>Coombs test positive<sup>3</sup>, increased serum gamma-glutamyl transpeptidase (GGT)<sup>1</sup>, increased serum alkaline phosphatase<sup>1</sup>, <em>Clostridioides</em> test positive<sup>2</sup></p></td></tr></tbody></table><p><sup>1</sup> Specific for the complicated intra-abdominal infections, acute pyelonephritis, and complicated urinary tract infections indications treated with Zerbaxa (1&nbsp;g&nbsp;/&nbsp;0.5&nbsp;g intravenously every 8&nbsp;hours) for up to 14&nbsp;days.</p><p><sup>2</sup> Specific for the hospital-acquired pneumonia, including ventilator-associated pneumonia indication treated with Zerbaxa (2&nbsp;g&nbsp;/&nbsp;1&nbsp;g intravenously every 8&nbsp;hours) for up to 14&nbsp;days.</p><p><sup>3</sup> Applies across all indications: complicated intra-abdominal infections, acute pyelonephritis, complicated urinary tract infections, and hospital-acquired pneumonia, including ventilator-associated pneumonia.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety assessment in paediatric patients, aged from birth to less than 18&nbsp;years, is based on the safety data from two trials in which 70&nbsp;patients with complicated intra‑abdominal infections and 100&nbsp;patients with complicated urinary tract infections (including acute pyelonephritis) received Zerbaxa. The safety profile in these 170&nbsp;paediatric patients was generally similar to that observed in the adult population with complicated intra‑abdominal infections and complicated urinary tract infections (including acute pyelonephritis). There were three additional adverse reactions observed in the paediatric population: neutropenia, increased appetite, and dysgeusia (all frequency common). The most common adverse reactions (&ge; 2% in pooled paediatric phase 2 trials) occurring in patients receiving Zerbaxa were diarrhoea, alanine aminotransferase increased, and aspartate aminotransferase increased. Safety data in patients less than 3&nbsp;months of age with complicated intra‑abdominal infections are limited.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Laboratory values</em></p><p>The development of a positive direct Coombs test may occur during treatment with Zerbaxa. The incidence of seroconversion to a positive direct Coombs test was 0.2% in patients receiving Zerbaxa and 0% in patients receiving the comparator in the adult complicated intra<strong>‑</strong>abdominal infections and complicated urinary tract infections clinical trials. The incidence of seroconversion to a positive direct Coombs test was 31.2% in patients receiving Zerbaxa and 3.6% in patients receiving meropenem in the adult hospital-acquired pneumonia, including ventilator-associated pneumonia clinical trial. The incidence of seroconversion to a positive direct Coombs test was 45.3% in patients receiving Zerbaxa and 33.3% in patients receiving meropenem in the paediatric complicated intra<strong>‑</strong>abdominal infection clinical trial. The incidence of seroconversion to a positive direct Coombs test was 29.7% in patients receiving Zerbaxa and 8.7% in patients receiving meropenem in the paediatric complicated urinary tract infection clinical trial. In clinical studies, there was no evidence of haemolysis in patients who developed a positive direct Coombs test in any treatment group.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Saudi Arabia: </u></p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>Other GCC States: </u></p><p>Please contact the relevant competent authorit</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no experience with overdose of Zerbaxa. The highest single dose of Zerbaxa used in clinical trials was 3&nbsp;g&nbsp;/&nbsp;1.5&nbsp;g of ceftolozane/tazobactam administered to healthy volunteers.</p><p>&nbsp;</p><p>In the event of overdose, Zerbaxa should be discontinued and general supportive treatment given. Zerbaxa can be removed by haemodialysis. Approximately 66% of ceftolozane, 56% of tazobactam, and 51% of the M1 metabolite of tazobactam were removed by dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>Pharmacotherapeutic group: Antibacterials for systemic use, other cephalosporins and penems, ATC&nbsp;code: J01DI54.</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p><u>&nbsp;</u></p><p>Ceftolozane belongs to the cephalosporin class of antimicrobials. Ceftolozane exerts bactericidal activity through binding to important penicillin‑binding proteins (PBPs), resulting in inhibition of bacterial cell‑wall synthesis and subsequent cell death.</p><p>&nbsp;</p><p>Tazobactam is a beta‑lactam structurally related to penicillins. It is an inhibitor of many molecular Class&nbsp;A beta-lactamases, including CTX‑M, SHV, and TEM enzymes. See below.</p><p>&nbsp;</p><p><u>Mechanisms of resistance</u></p><p><u>&nbsp;</u></p><p>Mechanisms of bacterial resistance to ceftolozane/tazobactam include:</p><p>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Production of beta‑lactamases that can hydrolyse ceftolozane and which are not inhibited by tazobactam (see below)</p><p>ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Modification of PBPs</p><p>&nbsp;</p><p>Tazobactam does not inhibit all Class A enzymes.</p><p>In addition tazobactam does not inhibit the following types of beta‑lactamase:</p><p>i.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AmpC enzymes (produced by Enterobacterales)</p><p>ii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serine‑based carbapenemases (e.g., <em>Klebsiella pneumoniae</em> carbapenemases [KPCs])</p><p>iii.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metallo‑beta‑lactamases (e.g., New Delhi metallo‑beta‑lactamase [NDM])</p><p>iv.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ambler Class D beta‑lactamases (OXA‑carbapenemases)</p><p>&nbsp;</p><p><u>Pharmacokinetic/pharmacodynamic relationship</u><u>s</u></p><p>&nbsp;</p><p>For ceftolozane the time that the plasma concentration exceeds the minimum inhibitory concentration of ceftolozane for the infecting organism has been shown to be the best predictor of efficacy in animal models of infection.</p><p>&nbsp;</p><p>For tazobactam the PD index associated with efficacy was determined to be the percentage of the dose interval during which the plasma concentration of tazobactam exceeds a threshold value (%T&nbsp;&gt;&nbsp;threshold). The time above a threshold concentration has been determined to be the parameter that best predicts the efficacy of tazobactam in <em>in vitro</em> and <em>in vivo</em> non-clinical models.</p><p>&nbsp;</p><p><u>Susceptibility testing breakpoints</u></p><p><u>&nbsp;</u></p><p>Minimum inhibitory concentration breakpoints established by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) are as follows:</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:94%"><thead><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>Minimum Inhibitory Concentrations (mg/L)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Pathogen</strong></p></td><td style="vertical-align:top"><p><strong>Type of Infection</strong></p></td><td style="vertical-align:top"><p><strong>Susceptible</strong></p></td><td style="vertical-align:top"><p><strong>Resistant </strong></p></td></tr><tr><td style="vertical-align:top"><p>Enterobacterales</p></td><td style="vertical-align:top"><p>Complicated intra‑abdominal infections*</p><p>Complicated urinary tract infections*</p><p>Acute pyelonephritis*</p><p>Hospital-acquired pneumonia, including ventilator‑associated pneumonia**</p></td><td style="vertical-align:top"><p>&le;&nbsp;2</p></td><td style="vertical-align:top"><p>&gt;&nbsp;2</p></td></tr><tr><td style="vertical-align:top"><p><em>P. aeruginosa</em></p></td><td style="vertical-align:top"><p>Complicated intra‑abdominal infections*</p><p>Complicated urinary tract infections*</p><p>Acute pyelonephritis*</p><p>Hospital-acquired pneumonia, including ventilator‑associated pneumonia**</p></td><td style="vertical-align:top"><p>&le;&nbsp;4</p></td><td style="vertical-align:top"><p>&gt;&nbsp;4</p></td></tr><tr><td style="vertical-align:top"><p><em>H. influenzae</em></p></td><td style="vertical-align:top"><p>Hospital-acquired pneumonia, including ventilator‑associated pneumonia**</p></td><td style="vertical-align:top"><p>&le;&nbsp;0.5</p></td><td style="vertical-align:top"><p>&gt;&nbsp;0.5</p></td></tr></thead></table><p>*Based on 1&nbsp;g ceftolozane&nbsp;/&nbsp;0.5&nbsp;g tazobactam intravenously every 8&nbsp;hours.</p><p>**Based on 2&nbsp;g ceftolozane&nbsp;/&nbsp;1&nbsp;g tazobactam intravenously every 8&nbsp;hours.</p><p>&nbsp;</p><p><u>Clinical efficacy against specific pathogens</u></p><p>Efficacy has been demonstrated in clinical studies against the pathogens listed under each indication that were susceptible to Zerbaxa<em> in vitro</em>:</p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Complicated intra‑abdominal infections</em></strong></p><p>&nbsp;</p><p><u>Gram‑negative bacteria</u></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli </em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Proteus mirabilis</em></p><p><em>Pseudomonas aeruginosa</em></p><p>&nbsp;</p><p><u>Gram‑positive bacteria</u></p><p><em>Streptococcus anginosus</em></p><p><em>Streptococcus constellatus</em></p><p><em>Streptococcus salivarius</em></p><p>&nbsp;</p><p><strong><em>Complicated urinary tract infections, including pyelonephritis </em></strong></p><p><u>Gram‑negative bacteria</u></p><p><em>Escherichia coli </em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Proteus mirabilis</em></p><p><strong><em>&nbsp;</em></strong></p><p><strong><em>Hospital-acquired pneumonia, including ventilator‑associated pneumonia</em></strong></p><p><em>&nbsp;</em></p><p><u>Gram‑negative bacteria</u></p><p><em>Enterobacter cloacae</em></p><p><em>Escherichia coli</em></p><p><em>Haemophilus influenzae</em></p><p><em>Klebsiella oxytoca</em></p><p><em>Klebsiella pneumoniae</em></p><p><em>Proteus mirabilis</em></p><p><em>Pseudomonas aeruginosa</em></p><p><em>Serratia marcescens</em></p><p>&nbsp;</p><p>Clinical efficacy has not been established against the following pathogens although <em>in vitro</em> studies suggest that they would be susceptible to Zerbaxa in the absence of acquired mechanisms of resistance:</p><p><em>Citrobacter freundii</em></p><p><em>Citrobacter koseri</em></p><p><em>Klebsiella (Enterobacter) aerogenes</em></p><p><em>Morganella morganii</em></p><p><em>Proteus vulgaris</em></p><p><em>Serratia liquefaciens</em></p><p><em>&nbsp;</em></p><p><em>In&nbsp;vitro </em>data indicate that the following species are not susceptible to ceftolozane/tazobactam:</p><p><em>Staphylococcus aureus</em></p><p><em>Enterococcus faecalis</em></p><p><em>Enterococcus faecium</em></p><p><strong><em>&nbsp;</em></strong></p><p><u>Paediatric population</u></p><p>Zerbaxa was evaluated in two blinded, randomised, active-controlled clinical trials in paediatric patients from birth (defined as &gt;&nbsp;32&nbsp;weeks gestational age and &ge;&nbsp;7&nbsp;days postnatal) to below&nbsp;18&nbsp;years of age, one in patients with complicated intra-abdominal infections (in combination with metronidazole), and the other in patients with complicated urinary tract infections and acute pyelonephritis. The primary objectives in these studies were to assess safety and tolerability of ceftolozane/tazobactam; efficacy was a secondary descriptive endpoint. Patients below 18&nbsp;years of age with eGFR &lt;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> (estimated using Bedside Schwartz equation) were excluded from these clinical trials. Additionally, data in patients below 3&nbsp;months of age with complicated intra‑abdominal infections are very limited (one patient in the Zerbaxa arm). Clinical cure rate at TOC (MITT) was 80.0% (56/70) for Zerbaxa compared to 100.0% (21/21) for meropenem in paediatric patients with complicated intra-abdominal infections. Microbiological eradication rate at TOC (mMITT) was 84.5% (60/71) for Zerbaxa compared to 87.5% (21/24) for meropenem in paediatric patients with acute pyelonephritis and complicated urinary tract infections.</p><p>&nbsp;</p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with Zerbaxa in one or more subsets of the paediatric population in hospital-acquired pneumonia, including ventilator-associated pneumonia (see section&nbsp;4.2 for information on paediatric use)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The C<sub>max</sub> and AUC of ceftolozane/tazobactam increase approximately in proportion to dose within ceftolozane single‑dose range of 250&nbsp;mg to 3&nbsp;g and tazobactam single‑dose range of 500&nbsp;mg to 1.5&nbsp;g. No appreciable accumulation of ceftolozane/tazobactam is observed following multiple 1‑hour IV infusions of 1&nbsp;g&nbsp;/&nbsp;0.5&nbsp;g ceftolozane/tazobactam or 2&nbsp;g&nbsp;/&nbsp;1&nbsp;g ceftolozane/tazobactam administered every 8&nbsp;hours for up to 10&nbsp;days in healthy adults with normal renal function. The elimination half‑life (t<sub>&frac12;</sub>) of ceftolozane or tazobactam is independent of dose.</p><p><u>&nbsp;</u></p><p><u>Distribution</u></p><p><u>&nbsp;</u></p><p>The binding of ceftolozane and tazobactam to human plasma proteins is low (approximately 16% to 21% and 30%, respectively).<sup> </sup>The mean (coefficient of variation CV%) steady‑state volume of distribution of ceftolozane/tazobactam in healthy adult males (n=51) following a single 1&nbsp;g&nbsp;/&nbsp;0.5&nbsp;g IV dose was 13.5&nbsp;L (21%) and 18.2&nbsp;L&nbsp;(25%) for ceftolozane and tazobactam, respectively, similar to extracellular fluid volume.</p><p>&nbsp;</p><p>Following 1&nbsp;hour intravenous infusions of 2&nbsp;g&nbsp;/&nbsp;1&nbsp;g ceftolozane/tazobactam or adjusted based on renal function every 8&nbsp;hours in ventilated adult patients with confirmed or suspected pneumonia (N=22), ceftolozane and tazobactam concentrations in pulmonary epithelial lining fluid were greater than 8&nbsp;mcg/mL and 1&nbsp;mcg/mL, respectively, over 100% of the dosing interval. Mean pulmonary epithelial‑to‑free plasma AUC ratios of ceftolozane and tazobactam were approximately 50% and 62%, respectively and are similar to those in healthy adult subjects (approximately 61% and 63%, respectively) receiving 1&nbsp;g&nbsp;/&nbsp;0.5&nbsp;g ceftolozane/tazobactam.</p><p><u>&nbsp;</u></p><p><u>Biotransformation</u></p><p><u>&nbsp;</u></p><p>Ceftolozane is eliminated in the urine as unchanged parent substance and thus does not appear to be metabolised to any appreciable extent. The beta‑lactam ring of tazobactam is hydrolysed to form the pharmacologically inactive, tazobactam metabolite M1.</p><p><u>&nbsp;</u></p><p><u>Elimination</u></p><p><u>&nbsp;</u></p><p>Ceftolozane, tazobactam and the tazobactam metabolite M1 are eliminated by the kidneys. Following administration of a single 1&nbsp;g&nbsp;/&nbsp;0.5&nbsp;g IV dose of ceftolozane/tazobactam to healthy male adults greater than 95% of ceftolozane was excreted in the urine as unchanged parent substance. More than 80% of tazobactam was excreted as the parent compound with the remaining amount excreted as the tazobactam M1 metabolite. After a single dose of ceftolozane/tazobactam, renal clearance of ceftolozane (3.41&nbsp;‑&nbsp;6.69&nbsp;L/h) was similar to plasma clearance (4.10&nbsp;‑&nbsp;6.73&nbsp;L/h) and similar to the glomerular filtration rate for the unbound fraction, suggesting that ceftolozane is eliminated by the kidney via glomerular filtration.</p><p>&nbsp;</p><p>The mean terminal elimination half‑life of ceftolozane and tazobactam in healthy adults with normal renal function is approximately 3&nbsp;hours and 1&nbsp;hour, respectively.</p><p>&nbsp;</p><p><u>Linearity</u><u>/non‑linearity</u></p><p>&nbsp;</p><p>The C<sub>max</sub> and AUC of ceftolozane/tazobactam increase in proportion to dose. Plasma levels of ceftolozane/tazobactam do not increase appreciably following multiple IV infusions of up to 2.0&nbsp;g&nbsp;/&nbsp;1.0&nbsp;g administered every 8&nbsp;hours for up to 10&nbsp;days in healthy adults with normal renal function. The elimination half‑life (t<sub>&frac12;</sub>) of ceftolozane is independent of dose.</p><p><strong>&nbsp;</strong></p><p><u>Special populations</u></p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p>Ceftolozane/tazobactam and the tazobactam metabolite M1 are eliminated by the kidneys.</p><p>&nbsp;</p><p>The ceftolozane dose normalised geometric mean AUC increased up to 1.26‑fold, 2.5‑fold, and 5‑fold in adults with mild, moderate, and severe renal impairment, respectively, compared to healthy adults with normal renal function. The respective tazobactam dose normalised geometric mean AUC increased approximately up to 1.3‑fold, 2‑fold, and 4‑fold. To maintain similar systemic exposures to those with normal renal function, dose adjustment is required (see section&nbsp;4.2)<em>.</em></p><p>&nbsp;</p><p>In adults with end stage renal disease on haemodialysis, approximately two‑thirds of the administered ceftolozane/tazobactam dose is removed by haemodialysis. The recommended dose in adults with end stage renal disease on haemodialysis with complicated intra‑abdominal infections or complicated urinary tract infections (including acute pyelonephritis) is a single loading dose of 500&nbsp;mg&nbsp;/&nbsp;250&nbsp;mg ceftolozane/tazobactam followed by a 100&nbsp;mg&nbsp;/&nbsp;50&nbsp;mg maintenance dose of ceftolozane/tazobactam administered every 8&nbsp;hours for the remainder of the treatment period. The recommended dose in adults with end stage renal disease on haemodialysis with hospital-acquired pneumonia, including ventilator-associated pneumonia is a single loading dose of 1.5&nbsp;g&nbsp;/&nbsp;0.75&nbsp;g ceftolozane/tazobactam followed by a 300&nbsp;mg&nbsp;/&nbsp;150&nbsp;mg maintenance dose of ceftolozane/tazobactam administered every 8&nbsp;hours for the remainder of the treatment period. With haemodialysis, the dose should be administered immediately following completion of dialysis (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Augmented renal clearance</em></p><p>Following a single 1-hour intravenous infusion of 2&nbsp;g&nbsp;/&nbsp;1&nbsp;g ceftolozane/tazobactam to critically ill adults with CrCL greater than or equal to 180&nbsp;mL/min (N=10), mean terminal half-life values of ceftolozane and tazobactam were 2.6&nbsp;hours and 1.5&nbsp;hours, respectively. Free plasma ceftolozane concentrations were greater than 8&nbsp;mcg/mL over 70% of an 8‑hour period; free tazobactam concentrations were greater than 1&nbsp;mcg/mL over 60% of an 8‑hour period. No dose adjustment of ceftolozane/tazobactam is recommended for hospital-acquired pneumonia, including ventilator-associated pneumonia in adults with augmented renal clearance.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>As ceftolozane/tazobactam does not undergo hepatic metabolism, the systemic clearance of ceftolozane/tazobactam is not expected to be affected by hepatic impairment. No dose adjustment is recommended for ceftolozane/tazobactam in subjects with hepatic impairment (see section&nbsp;4.2).</p><p><u>&nbsp;</u></p><p><em>Elderly</em></p><p>In a population pharmacokinetic analysis of ceftolozane/tazobactam, no clinically relevant differences in exposure were observed with regard to age. No dose adjustment of ceftolozane/tazobactam based on age alone is recommended.</p><p>&nbsp;</p><p><em>Paediatric patients</em></p><p>For Zerbaxa dose recommendations in paediatric patients with complicated intra‑abdominal infections and complicated urinary tract infections, including pyelonephritis, refer to Table&nbsp;2 in section&nbsp;4.2.</p><p>&nbsp;</p><p>The pharmacokinetics of ceftolozane and tazobactam in paediatric patients (below 18&nbsp;years of age) were evaluated in one Phase&nbsp;1 study (in proven or suspected gram‑negative infection) and two Phase&nbsp;2 studies (in complicated intra‑abdominal infections and in complicated urinary tract infections, including pyelonephritis). The data from these three studies were pooled and population pharmacokinetic modelling was conducted to estimate paediatric individual steady‑state AUC<sub> </sub>and C<sub>max</sub> as well as to perform simulations to assess PK/PD probability of target attainment (PTA).</p><p>&nbsp;</p><p>The individual steady‑state AUC and C<sub>max</sub> for ceftolozane and tazobactam, in paediatric patients aged 2 to below&nbsp;18&nbsp;years with complicated intra‑abdominal infections or complicated urinary tract infections were generally similar to adults. There is limited experience with the use of ceftolozane and tazobactam in paediatric patients below 2&nbsp;years of age. The recommended dose regimens in these paediatric patients were based on simulations conducted using population pharmacokinetic models, and no clinically relevant differences in steady‑state AUC and C<sub>max</sub> are expected between paediatric patients under 2&nbsp;years and older children and adults.</p><p>&nbsp;</p><p>There was insufficient clinical pharmacokinetic data in paediatric patients with eGFR &le;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> with complicated intra‑abdominal infections or complicated urinary tract infections to recommend a dose regimen for paediatric patients with eGFR &le;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>.</p><p>&nbsp;</p><p><em>Gender</em></p><p>In a population pharmacokinetic analysis of ceftolozane/tazobactam, no clinically relevant differences in AUC were observed for ceftolozane and tazobactam. No dose adjustment is recommended based on gender.</p><p><u>&nbsp;</u></p><p><em>Ethnicity</em></p><p>In a population pharmacokinetic analysis of ceftolozane/tazobactam, no clinically relevant differences in ceftolozane/tazobactam AUC were observed in Caucasians compared to other ethnicities. No dose adjustment is recommended based on race.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity in adult and juvenile animals, or genotoxicity. Carcinogenicity studies with ceftolozane/tazobactam have not been conducted.</p><p>&nbsp;</p><p>Effects in non‑clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.</p><p>&nbsp;</p><p>Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows: ceftolozane administered to rats during pregnancy and breast-feeding was associated with a decrease in auditory startle response in postnatal day (PND) 60&nbsp;male pups at maternal doses of 300 and 1&nbsp;000&nbsp;mg/kg/day. A dose of 300&nbsp;mg/kg/day to rats was associated with a ceftolozane plasma exposure (AUC) value lower than the ceftolozane plasma AUC value at the highest recommended human dose of 2&nbsp;grams every 8&nbsp;hours.</p><p>&nbsp;</p><p>Peri/postnatal development was impaired (reduced pup weights, increase in stillbirths, increase in pup mortality) concurrent with maternal toxicity after intraperitoneal administration of tazobactam in the rat.</p><p>&nbsp;</p><p><u>Environmental risk assessment (ERA)</u></p><p>&nbsp;</p><p>Environmental risk assessment studies have shown that one of the active ingredients, ceftolozane, may pose a risk to surface water organisms (see section&nbsp;6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Sodium chloride</p><p>Arginine</p><p>Citric acid, anhydrous</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>This medicinal product must not be mixed with other medicinal products except those mentioned in section&nbsp;6.6.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.

After reconstitution and dilution, chemical and physical in use stability has been demonstrated for 24 hours at room temperature or 4 days at 2 to 8 ºC. The medicinal product is photosensitive and should be protected from light when not stored in the original carton.

From a microbiological point of view, the medicinal product should be used immediately upon reconstitution. If not used immediately, in use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 ºC, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&nbsp;&ordm;C&nbsp;&ndash;&nbsp;8&nbsp;&ordm;C).</p><p>&nbsp;</p><p>Store in the original package in order to protect from light.</p><p>&nbsp;</p><p>For storage conditions after reconstitution and dilution of the medicinal product, see section&nbsp;6.3.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>20&nbsp;mL vial (Type&nbsp;I clear glass) with stopper (bromobutyl rubber) and flip‑off seal.</p><p>&nbsp;</p><p>Pack size of 10&nbsp;vials</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each vial is for single use only.</p><p>&nbsp;</p><p>Aseptic technique must be followed in preparing the infusion solution.</p><p>&nbsp;</p><p><u>Preparation of doses</u></p><p>&nbsp;</p><p>The powder for concentrate for solution for infusion for each vial is reconstituted with 10&nbsp;mL of water for injections or sodium chloride 9&nbsp;mg/mL (0.9%) solution for injection per vial; following reconstitution the vial should be shaken gently to dissolve the powder. The final volume is approximately 11.4&nbsp;mL per vial. The resultant concentration is approximately 132&nbsp;mg/mL (88&nbsp;mg/mL of ceftolozane and 44&nbsp;mg/mL of tazobactam) per vial.</p><p>&nbsp;</p><p>CAUTION: THE RECONSTITUTED SOLUTION IS NOT FOR DIRECT INJECTION.</p><p>&nbsp;</p><p>Zerbaxa solution for infusion is clear and colourless to slightly yellow.</p><p>&nbsp;</p><p>Variations in colour within this range do not affect the potency of the product.</p><p>&nbsp;</p><p>See section&nbsp;4.2 for recommended dose regimens for Zerbaxa based on indication and renal function. The preparation for each dose is shown below.</p><p>&nbsp;</p><p><u>Instructions for preparing adult doses in INFUSION BAG:</u></p><p>&nbsp;</p><p>For preparation of the 2&nbsp;g&nbsp;ceftolozane&nbsp;/&nbsp;1&nbsp;g&nbsp;tazobactam dose: Withdraw the entire contents from two&nbsp;reconstituted vials (approximately 11.4&nbsp;mL per vial) using a syringe and add it to an infusion bag containing 100&nbsp;mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.</p><p>&nbsp;</p><p>For preparation of the 1.5&nbsp;g&nbsp;ceftolozane&nbsp;/&nbsp;0.75&nbsp;g&nbsp;tazobactam dose: Withdraw the entire contents from one&nbsp;reconstituted vial (approximately 11.4&nbsp;mL per vial) and 5.7&nbsp;mL from a second reconstituted vial using a syringe and add it to an infusion bag containing 100&nbsp;mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.</p><p>&nbsp;</p><p>For preparation of the 1&nbsp;g&nbsp;ceftolozane&nbsp;/&nbsp;0.5&nbsp;g&nbsp;tazobactam dose: Withdraw the entire contents (approximately 11.4&nbsp;mL) of the reconstituted vial using a syringe and add it to an infusion bag containing 100&nbsp;mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.</p><p>&nbsp;</p><p>For preparation of the 500&nbsp;mg&nbsp;ceftolozane&nbsp;/&nbsp;250&nbsp;mg&nbsp;tazobactam dose: Withdraw 5.7&nbsp;mL of the contents of the reconstituted vial and add it to an infusion bag containing 100&nbsp;mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.</p><p>&nbsp;</p><p>For preparation of the 300&nbsp;mg&nbsp;ceftolozane&nbsp;/&nbsp;150&nbsp;mg&nbsp;tazobactam dose: Withdraw 3.5&nbsp;mL of the contents of the reconstituted vial and add it to an infusion bag containing 100&nbsp;mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.</p><p>&nbsp;</p><p>For preparation of the 250&nbsp;mg&nbsp;ceftolozane&nbsp;/&nbsp;125&nbsp;mg&nbsp;tazobactam dose: Withdraw 2.9&nbsp;mL of the contents of the reconstituted vial and add it to an infusion bag containing 100&nbsp;mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.</p><p>&nbsp;</p><p>For preparation of the 100&nbsp;mg&nbsp;ceftolozane&nbsp;/&nbsp;50&nbsp;mg&nbsp;tazobactam dose: Withdraw 1.2&nbsp;mL of the contents of the reconstituted vial and add it to an infusion bag containing 100&nbsp;mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.</p><p><u>&nbsp;</u></p><p><u>Instructions for preparing paediatric doses in INFUSION BAG or in INFUSION SYRINGE:</u></p><p>&nbsp;</p><p>NOTE: The following procedure describes the steps to prepare 100&nbsp;mL of stock solution with a final concentration of 10&nbsp;mg/mL ceftolozane&nbsp;/&nbsp;5&nbsp;mg/mL tazobactam. The volume of this stock solution to be administered to the paediatric patient will be based on calculating the appropriate dose based on the patient&rsquo;s weight (see section&nbsp;4.2). Detailed steps and calculations are provided.</p><p>&nbsp;</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp; Preparing the stock solution (100&nbsp;mL of 10&nbsp;mg/mL ceftolozane&nbsp;/&nbsp;5&nbsp;mg/mL tazobactam): Withdraw the entire contents (approximately 11.4&nbsp;mL) of the reconstituted vial using a syringe and add it to an infusion bag containing 89&nbsp;mL of 0.9% sodium chloride for injection (normal saline) or 5% glucose injection.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp; Preparing the required volume of stock solution for infusion:</p><p>a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculate the appropriate amount of Zerbaxa (in mg) to deliver the required dose to the paediatric patient. Based on this dose in mg, calculate the appropriate volume of the 10&nbsp;mg/mL ceftolozane&nbsp;/&nbsp;5&nbsp;mg/mL tazobactam stock solution to be administered. Refer to Table&nbsp;5 below to confirm the calculations. Note that the table is NOT inclusive of all possible calculated doses but may be utilised to estimate the approximate volume to verify the calculation.</p><p>b.&nbsp;&nbsp;&nbsp;&nbsp; Transfer an appropriately calculated volume of stock solution to an adequately sized infusion bag or infusion syringe. Values shown in Table&nbsp;5 are approximate, and it may be necessary to round to the nearest graduation mark of an appropriately sized syringe for smaller volumes.</p><p>&nbsp;</p><p><strong>Table 5: Preparation of Zerbaxa for paediatric patients (from birth* to below 18&nbsp;years of age) from the 100&nbsp;mL stock solution of 10&nbsp;mg/mL ceftolozane&nbsp;/&nbsp;5&nbsp;mg/mL tazobactam</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td><p><strong>Zerbaxa dose (mg/kg)</strong></p></td><td><p><strong>Weight (kg)</strong></p></td><td><p><strong>Calculated amount of ceftolozane (mg)</strong></p></td><td><p><strong>Calculated amount of tazobactam (mg)</strong></p></td><td><p><strong>Volume of stock solution to administer to patient (mL)</strong></p></td></tr></thead><tbody><tr><td rowspan="9"><p>20&nbsp;mg/kg ceftolozane / 10&nbsp;mg/kg tazobactam**</p></td><td><p>50 and greater</p></td><td><p>1&nbsp;000</p></td><td><p>500</p></td><td><p>100</p></td></tr><tr><td><p>40</p></td><td><p>800</p></td><td><p>400</p></td><td><p>80</p></td></tr><tr><td><p>30</p></td><td><p>600</p></td><td><p>300</p></td><td><p>60</p></td></tr><tr><td><p>20</p></td><td><p>400</p></td><td><p>200</p></td><td><p>40</p></td></tr><tr><td><p>15</p></td><td><p>300</p></td><td><p>150</p></td><td><p>30</p></td></tr><tr><td><p>10</p></td><td><p>200</p></td><td><p>100</p></td><td><p>20</p></td></tr><tr><td><p>5</p></td><td><p>100</p></td><td><p>50</p></td><td><p>10</p></td></tr><tr><td><p>3</p></td><td><p>60</p></td><td><p>30</p></td><td><p>6</p></td></tr><tr><td><p>1.5</p></td><td><p>30</p></td><td><p>15</p></td><td><p>3</p></td></tr></tbody></table><p>*Defined as &gt;&nbsp;32&nbsp;weeks gestational age and &ge;&nbsp;7&nbsp;days postnatal.</p><p>**Children weighing &gt;&nbsp;50&nbsp;kg and with eGFR &gt;&nbsp;50&nbsp;mL/min/1.73&nbsp;m<sup>2</sup> should not exceed the maximum dose of 1&nbsp;g ceftolozane&nbsp;/&nbsp;0.5&nbsp;g tazobactam.</p><p>&nbsp;</p><p>One of the active ingredients, ceftolozane, may have harmful effects if it reaches the aquatic environment (see section&nbsp;5.3). Do not throw away any unused medicinal product or waste material via wastewater. Any unused medicinal product or waste material should be disposed of in accordance with local requirements. These measures will help protect the environment</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Marketing Authorization Holder: 
Merck Sharp & Dohme B.V.
Waarderweg 39
2031 BN Haarlem
The Netherlands

Manufacturers:
Steri-Pharma, LLC
429 S. West Street, NY, Syracuse, 13202, United States

Fareva Mirabel - FR Route de Marsat RIOM, Clermont Ferrand Cedex 9, 63963 FR
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2022

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>